Get the Stockscreener App
1.46
0.00%
0.00
After Hours:
1.46
Milestone Pharmaceuticals Inc stock is traded at $1.46, with a volume of 340.92K.
It is up +0.00% in the last 24 hours and up +8.96% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.46
Open:
$1.47
24h Volume:
340.92K
Relative Volume:
3.10
Market Cap:
$77.77M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.0657
EPS:
-1.37
Net Cash Flow:
$-46.54M
1W Performance:
+2.82%
1M Performance:
+8.96%
6M Performance:
+0.69%
1Y Performance:
-51.33%
1-Day Range:
$1.41
$1.51
1-Week Range:
$1.36
$1.55
52-Week Range:
$1.12
$3.52
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Etripamil nasal spray shows promise in China trial - Investing.com
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China - GlobeNewswire Inc.
Milestone Pharmaceuticals welcomes new board member Joseph Papa - Investing.com
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors - GlobeNewswire Inc.
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Brokers Offer Predictions for Milestone Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:MIST) - MarketBeat
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024 - StockTitan
HC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals (NASDAQ:MIST) Given “Buy” Rating at HC Wainwright - Defense World
Rodman & Renshaw Initiates Coverage of Milestone Pharmaceuticals (MIST) with Buy Recommendation - MSN
HC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from Analysts at Rodman & Renshaw - MarketBeat
Milestone stock wins Buy at Rodman Renshaw (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Rodman & Renshaw - Defense World
Thinking about buying stock in Cellebrite DI, Milestone Pharmace - GuruFocus.com
Thinking about buying stock in Mogo Inc, Rigetti Computing, Apte - GuruFocus.com
Milestone Pharmaceuticals: Q2 Earnings Snapshot - CTPost
MISTMilestone Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Milestone Pharmaceuticals: Q2 Earnings Snapshot - CT Insider
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Antonio Express-News
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - wallstreet:online
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - StockTitan
Agios Pharmaceuticals' Shares Rise Ahead of $1.1B in Milestone Payments - MarketWatch
Contrasting AstraZeneca (NASDAQ:AZN) & Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
SIPP Industries Announces Milestone Achievements in Partnership with Calypso Pharmaceuticals - StockTitan
Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference - StockTitan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stake Boosted by BNP Paribas Financial Markets - Defense World
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com India
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com Nigeria
Mirum Pharmaceuticals hits all-time high at $40.76, marking a significant milestone - Investing.com
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 2.7% Higher - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 2.7% Higher - Defense World
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties - GlobeNewswire
Milestone Pharmaceuticals adds two new board members - Investing.com India
Milestone Pharmaceuticals adds two new board members By Investing.com - Investing.com Canada
Milestone Pharmaceuticals adds two new board members - Investing.com
Milestone Pharmaceuticals Refreshes Board of Directors - StockTitan
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 - StockTitan
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration - Yahoo Finance
Lipigon Pharmaceuticals Receives Milestone Payment of USD 1 Million from Leaderna Therapeutics Ltd for Approval of Phase I Bridging Study - Marketscreener.com
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Milestone Pharma stock holds buy rating at H.C. Wainwright on expansion potential By Investing.com - Investing.com UK
Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright - Defense World
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher - Defense World
Top Ranked Momentum Stocks to Buy for May 19th - Yahoo Lifestyle UK
Nothing is Better Than Milestone Pharmaceuticals Inc (MIST) stock at the moment – Sete News - SETE News
Revir Therapeutics and Asieris announce milestone under oncology collaboration - BioWorld Online
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):